Circulating endothelin-1 levels are positively associated with chronic kidney disease in women but not in men: a longitudinal study in the Vara-Skövde cohort.
Endothelin-1
Epidemiology
Gender
Kidney disease
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
02 10 2021
02 10 2021
Historique:
received:
08
03
2021
accepted:
09
06
2021
entrez:
3
10
2021
pubmed:
4
10
2021
medline:
11
3
2022
Statut:
epublish
Résumé
The vasoconstricting peptide endothelin-1 (ET-1) is associated with endothelial dysfunction. The aim of this paper was to investigate whether circulating ET-1 levels predicts chronic kidney disease (CKD) in a prospective population study. In 2002-2005, 2816 participants (30-74 years) were randomly selected from two municipalities in South-Western Sweden and followed up in a representative sample of 1327 individuals after 10 years. Endothelin-1 levels were assessed at baseline. Outcome was defined as CKD stage 3 or above based on eGFR < 60 mL/min/1.73m At follow-up, 51 (8%) men and 47 (7,8%) women had CKD stage 3 and above. Based on levels of ET-1 the population was divided into quintiles showing that women in the highest quintile (n = 132) had a significantly increased risk of developing CKD during the follow up period (OR = 2.54, 95% CI:1.19-5.45, p = 0.02) compared with the other quintiles (1-4). The association was borderline significant after adjusted for age, current smoking, alcohol consumption, hypertension, diabetes, BMI, high- sensitive CRP and LDL-cholesterol (OR = 2.25, 95% CI:0.97-5.24, p = 0.06). No significant differences were observed between quintiles of ET-1 and development of CKD in men (NS). High levels of ET-1 are associated with development of CKD in women.
Sections du résumé
BACKGROUND
The vasoconstricting peptide endothelin-1 (ET-1) is associated with endothelial dysfunction. The aim of this paper was to investigate whether circulating ET-1 levels predicts chronic kidney disease (CKD) in a prospective population study.
METHODS
In 2002-2005, 2816 participants (30-74 years) were randomly selected from two municipalities in South-Western Sweden and followed up in a representative sample of 1327 individuals after 10 years. Endothelin-1 levels were assessed at baseline. Outcome was defined as CKD stage 3 or above based on eGFR < 60 mL/min/1.73m
RESULTS
At follow-up, 51 (8%) men and 47 (7,8%) women had CKD stage 3 and above. Based on levels of ET-1 the population was divided into quintiles showing that women in the highest quintile (n = 132) had a significantly increased risk of developing CKD during the follow up period (OR = 2.54, 95% CI:1.19-5.45, p = 0.02) compared with the other quintiles (1-4). The association was borderline significant after adjusted for age, current smoking, alcohol consumption, hypertension, diabetes, BMI, high- sensitive CRP and LDL-cholesterol (OR = 2.25, 95% CI:0.97-5.24, p = 0.06). No significant differences were observed between quintiles of ET-1 and development of CKD in men (NS).
CONCLUSIONS
High levels of ET-1 are associated with development of CKD in women.
Identifiants
pubmed: 34600499
doi: 10.1186/s12882-021-02525-5
pii: 10.1186/s12882-021-02525-5
pmc: PMC8487112
doi:
Substances chimiques
Endothelin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Informations de copyright
© 2021. The Author(s).
Références
Lancet. 1994 Sep 24;344(8926):852-4
pubmed: 7916401
Lancet. 2010 Apr 10;375(9722):1296-309
pubmed: 20382326
Diabetes Res Clin Pract. 2016 Mar;113:33-7
pubmed: 26972958
Int J Cardiol. 2013 Oct 15;168(6):5416-21
pubmed: 24051266
Semin Nephrol. 2015 Mar;35(2):156-67
pubmed: 25966347
Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1569-H1588
pubmed: 30216121
J Cardiovasc Transl Res. 2020 Feb;13(1):47-54
pubmed: 31044374
Clin Biochem. 2015 Mar;48(4-5):292-6
pubmed: 25541019
Circ J. 2012;76(12):2779-84
pubmed: 22971991
BMC Public Health. 2008 Apr 11;8:117
pubmed: 18405348
Am J Physiol Renal Physiol. 2003 Oct;285(4):F579-89
pubmed: 12954590
Kidney Int. 1984 Dec;26(6):861-8
pubmed: 6533397
J Clin Hypertens (Greenwich). 2016 Feb;18(2):95-100
pubmed: 26234374
Hypertension. 2019 Dec;74(6):1232-1265
pubmed: 31679425
J Clin Endocrinol Metab. 2001 Oct;86(10):4666-73
pubmed: 11600523
BMC Cardiovasc Disord. 2015 Nov 14;15:146
pubmed: 26573599
Curr Opin Nephrol Hypertens. 2016 Jan;25(1):35-41
pubmed: 26625864
Nephron. 2016;134(1):25-9
pubmed: 27050529
Adv Chronic Kidney Dis. 2018 Mar;25(2):121-132
pubmed: 29580576
Clin Kidney J. 2012 Feb;5(1):17-27
pubmed: 26069741
Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R261-5
pubmed: 19939973
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Trends Cardiovasc Med. 2020 Jan;30(1):1-8
pubmed: 30765295
Circulation. 2003 Oct 28;108(17):2154-69
pubmed: 14581387